A) Scheme of administration | ||||||
| ||||||
B) | ||||||
Constructs and controls | Lifespan, days | ILS,% | TGD 500mm3, days | FLM,% | Volume of lymph nodes, mm 3 | MI,% |
TKmGM-PPT/GCV | 60 ± 22 | 70* | 14.1 | 33* | 100 ± 45 | 82* |
TK-PPT/GCV | 57 ± 15 | 62* | 11.6 | 58* | 186 ± 80 | 67* |
mGM-PPT/GCV | 39 ± 13 | 9 | 4.1 | 50* | 189 ± 91 | 66 |
TKmGM-PPT/PBS | 41 ± 7 | 16 | 3.9 | 42* | 298 ± 264 | 47 |
TK-PPT/PBS | 38 ± 4 | 8 | 2.6 | 75 | 459 ± 339 | 18 |
mGM-PPT/PBS | 48 ± 4 | 35 | 3.0 | 58* | 349 ± 242 | 38 |
Control/GCV | 40 ± 3 | 6 | 0.3 | 100 | 457 ± 121 | 19 |
Control/PBS | 35 ± 3 | - |  | 100 | 562 ± 316 |  |